Should I Buy ONCY? ONCY 2026 Analysis

Should You Buy Oncolytics Biotech Inc (ONCY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.110

1 Day change

-4.31%

52 Week Range

1.510

Analysis Updated At

2026/01/26

Oncolytics Biotech Inc (ONCY) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has bullish technical indicators and a positive analyst rating, the lack of recent news, stagnant revenue growth, and no significant trading trends suggest limited immediate upside. The stock may be worth monitoring for future developments, particularly regarding its FDA meeting and potential regulatory advancements.

Technical Analysis

The technical indicators for ONCY are bullish. The MACD is positive and expanding, moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its resistance level (R1: 1.241). However, the RSI is in the neutral zone, and the stock has shown a slight downward trend in recent trading sessions.

Options Data

Positive Catalysts

H.C. Wainwright raised the price target to $10 from $5, citing compelling data in gastrointestinal tumors and confidence in regulatory pathways for pelareorep. Bullish technical indicators support potential upward movement.

Neutral/Negative Catalysts

The stock has experienced a consistent price decline (-2.36% in regular market and -0.40% post-market). Additionally, there is no recent news or significant trading trends from hedge funds or insiders. Financial performance remains weak with stagnant revenue and negative net income.

Financial Performance

In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 50.90% YoY but remains negative at -$14.4M. EPS increased by 16.67% YoY to -0.14, but the company is still unprofitable. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating and raised the price target to $10, citing confidence in the company's regulatory advancements and compelling data in cancer indications.

6 Analyst Rating

Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.5 USD with a low forecast of 3 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.160

Low

Averages

5.5

High

Current: 1.160

Low

Averages

5.5

High

H.C. Wainwright

upgrade

$5 -> $10

AI Analysis

2025-11-17

Reason

H.C. Wainwright

Price Target

$5 -> $10

AI Analysis

2025-11-17

upgrade

Reason

H.C. Wainwright raised the firm's price target on Oncolytics to $10 from $5 and keeps a Buy rating on the shares. The firm says the company's "compelling" data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward "actionable regulatory pathways" across three "high-value" cancer indications.

Lake Street

Chad Messer

initiated

2025-08-13

Reason

Lake Street

Chad Messer

Price Target

2025-08-13

initiated

Reason

Lake Street analyst Chad Messer initiated coverage of Oncolytics with a Buy rating and $7 price target. Oncolytics is emerging under new management with a clear pivotal strategy focused in frontline metastatic pancreatic ductal adenocarcinoma, where \"existing clinical data is strong and the unmet need is clear,\" the analyst tells investors. Pelareorep has shown \"impressive\" increases in survival compared to both historical results and in a randomized study when added to standard of care regimens, added the analyst, who also notes that the FDA has granted fast track designation to pelareorep in pancreatic cancer.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ONCY

Unlock Now

ONCY Should I Buy

ONCY Should I Buy

Should You Buy Oncolytics Biotech Inc (ONCY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch